These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38888299)
1. Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs. Walther R; Park M; Ashman N; Welch M; Carroll JS; Spring DR Chem Commun (Camb); 2024 Jul; 60(55):7025-7028. PubMed ID: 38888299 [TBL] [Abstract][Full Text] [Related]
2. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. Edupuganti VVSR; Tyndall JDATDA; Gamble AB Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624 [TBL] [Abstract][Full Text] [Related]
3. Copper-Triggered Bioorthogonal Cleavage Reactions for Reversible Protein and Cell Surface Modifications. Wang X; Liu Y; Fan X; Wang J; Ngai WSC; Zhang H; Li J; Zhang G; Lin J; Chen PR J Am Chem Soc; 2019 Oct; 141(43):17133-17141. PubMed ID: 31580665 [TBL] [Abstract][Full Text] [Related]
4. Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Wang Y; Xie F; Liu L; Xu X; Fan S; Zhong W; Zhou X Drug Deliv; 2022 Dec; 29(1):754-766. PubMed ID: 35244495 [TBL] [Abstract][Full Text] [Related]
5. Stabilizing p-Dithiobenzyl Urethane Linkers without Rate-Limiting Self-Immolation for Traceless Drug Release. Zheng Y; Shen Y; Meng X; Wu Y; Zhao Y; Wu C ChemMedChem; 2019 Jun; 14(12):1196-1203. PubMed ID: 31020782 [TBL] [Abstract][Full Text] [Related]
6. Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs. Zheng K; Chen Y; Wang J; Zheng L; Hutchinson M; Persson J; Ji J J Pharm Sci; 2019 Jan; 108(1):133-141. PubMed ID: 30458165 [TBL] [Abstract][Full Text] [Related]
7. Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry. Ferhati X; Jiménez-Moreno E; Hoyt EA; Salluce G; Cabeza-Cabrerizo M; Navo CD; Compañón I; Akkapeddi P; Matos MJ; Salaverri N; Garrido P; Martínez A; Laserna V; Murray TV; Jiménez-Osés G; Ravn P; Bernardes GJL; Corzana F J Am Chem Soc; 2022 Mar; 144(12):5284-5294. PubMed ID: 35293206 [TBL] [Abstract][Full Text] [Related]
8. Drug Release from Disulfide-Linked Prodrugs: Role of Thiol Agents. Lei J; Zhang Q; Jin X; Lu H; Wang S; Li T; Sheng Y; Zhang F; Zheng Y Mol Pharm; 2021 Jul; 18(7):2777-2785. PubMed ID: 34121410 [TBL] [Abstract][Full Text] [Related]
9. Cleavable linkers in antibody-drug conjugates. Bargh JD; Isidro-Llobet A; Parker JS; Spring DR Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429 [TBL] [Abstract][Full Text] [Related]
10. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629 [TBL] [Abstract][Full Text] [Related]
11. Mutual prodrugs containing bio-cleavable and drug releasable disulfide linkers. Jain AK; Gund MG; Desai DC; Borhade N; Senthilkumar SP; Dhiman M; Mangu NK; Mali SV; Dubash NP; Halder S; Satyam A Bioorg Chem; 2013 Aug; 49():40-8. PubMed ID: 23886697 [TBL] [Abstract][Full Text] [Related]
12. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates. Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates. Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351 [TBL] [Abstract][Full Text] [Related]
14. Development of Antibody-Directed Therapies: Quo Vadis? Rodrigues T; Bernardes GJL Angew Chem Int Ed Engl; 2018 Feb; 57(8):2032-2034. PubMed ID: 29341367 [TBL] [Abstract][Full Text] [Related]
15. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Chen H; Lin Z; Arnst KE; Miller DD; Li W Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044 [TBL] [Abstract][Full Text] [Related]
16. Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates. Giese M; Davis PD; Woodman RH; Hermanson G; Pokora A; Vermillion M Bioconjug Chem; 2021 Oct; 32(10):2257-2267. PubMed ID: 34587447 [TBL] [Abstract][Full Text] [Related]
17. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)]. Tsuchikama K Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230 [TBL] [Abstract][Full Text] [Related]
18. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides. Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744 [TBL] [Abstract][Full Text] [Related]
19. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Staben LR; Koenig SG; Lehar SM; Vandlen R; Zhang D; Chuh J; Yu SF; Ng C; Guo J; Liu Y; Fourie-O'Donohue A; Go M; Linghu X; Segraves NL; Wang T; Chen J; Wei B; Phillips GD; Xu K; Kozak KR; Mariathasan S; Flygare JA; Pillow TH Nat Chem; 2016 Dec; 8(12):1112-1119. PubMed ID: 27874860 [TBL] [Abstract][Full Text] [Related]
20. Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads. Lerchen HG; Stelte-Ludwig B; Sommer A; Berndt S; Rebstock AS; Johannes S; Mahlert C; Greven S; Dietz L; Jörißen H Bioconjug Chem; 2020 Aug; 31(8):1893-1898. PubMed ID: 32667786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]